5 research outputs found

    О состоянии статистики занятости ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² Π² России

    Get PDF
    Ensuring the equal employment opportunities for persons with disabilities is one of the priorities of public support for people with disabilities in Russia. This determines the need for detailed, reliable and timely statistics on the position of persons with disabilities in the labor market. The authors analyzed the content and quality of statistics collected in this area, considering, in particular, the recent methodological, organizational and statistical innovations - inclusion of the questions about disability status in the key population surveys and creation of the Federal Register of Disabled Persons (FRD).The article notes that to date, estimates of the employment rate of persons with disabilities on the basis of administrative data and labor force survey differ, which justifies the need for an additional analysis of the methodology of these indicators. Thus, data of the FRD contains information about all people with disability status in Russia, but information on their employment covers mostly employment in the formal sector. While the population survey data, according to the authors, on the contrary, make it possible to take into account allforms of employΒ¬ment, but face the problem of underestimating of people with disabilities due to the design of the questions used, the reluctance of individuals to declare disability, and due to the fact that some groups of people with disabilities are less likely to be respondents of the surveys. In addition, the administrative data and the labor force survey data differ in the length of the reference period and methodology of calculation of annual indicators.According to the authors analysis, administrative data reflects the number of employed persons with disabilities more objectively, while for detailed characteristics of disabled people position in the labor market population survey data may be used.ΠžΠ±Π΅ΡΠΏΠ΅Ρ‡Π΅Π½ΠΈΠ΅ Ρ€Π°Π²Π½ΠΎΠ³ΠΎ доступа ΠΈ Ρ€Π°Π²Π½Ρ‹Ρ… возмоТностСй для Π»ΠΈΡ† с ΠΈΠ½Π²Π°Π»ΠΈΠ΄Π½ΠΎΡΡ‚ΡŒΡŽ Π½Π° Ρ€Ρ‹Π½ΠΊΠ΅ Ρ‚Ρ€ΡƒΠ΄Π° являСтся ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΏΡ€ΠΈΠΎΡ€ΠΈΡ‚Π΅Ρ‚ΠΎΠ² государствСнной ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠΊΠΈ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² Π² России. Π­Ρ‚ΠΎ опрСдСляСт ΠΏΠΎΡ‚Ρ€Π΅Π±Π½ΠΎΡΡ‚ΡŒ Π² ΠΏΠΎΠ΄Ρ€ΠΎΠ±Π½ΠΎΠΉ, достовСрной ΠΈ ΠΎΠΏΠ΅Ρ€Π°Ρ‚ΠΈΠ²Π½ΠΎΠΉ статистикС ΠΎ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΈ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² Π½Π° Ρ€Ρ‹Π½ΠΊΠ΅ Ρ‚Ρ€ΡƒΠ΄Π°. Авторы ΠΏΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π»ΠΈ содСрТаниС ΠΈ качСство собираСмых статистичСских Π΄Π°Π½Π½Ρ‹Ρ… Π² этой области, рассмотрСв, Π² частности, мСтодологичСскиС ΠΈ ΠΎΡ€Π³Π°Π½ΠΈΠ·Π°Ρ†ΠΈΠΎΠ½Π½ΠΎ-статистичСскиС Π½ΠΎΠ²Π°Ρ†ΠΈΠΈ послСднСго Π²Ρ€Π΅ΠΌΠ΅Π½ΠΈ - Π²ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅ вопроса ΠΎ Π½Π°Π»ΠΈΡ‡ΠΈΠΈ статуса ΠΈΠ½Π²Π°Π»ΠΈΠ΄Π° Π² ΠΊΠ»ΡŽΡ‡Π΅Π²Ρ‹Π΅ обслСдования насСлСния ΠΈ созданиС Π€Π΅Π΄Π΅Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ рССстра ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² (ЀРИ).Π’ ΡΡ‚Π°Ρ‚ΡŒΠ΅ отмСчаСтся, Ρ‡Ρ‚ΠΎ ΠΈ Π½Π° сСгодняшний дСнь ΠΎΡ†Π΅Π½ΠΊΠΈ уровня занятости ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² ΠΏΠΎ административным Π΄Π°Π½Π½Ρ‹ΠΌ ΠΈ ΠΏΠΎ Π΄Π°Π½Π½Ρ‹ΠΌ обслСдования Ρ€Π°Π±ΠΎΡ‡Π΅ΠΉ силы расходятся, Ρ‡Ρ‚ΠΎ обосновываСт Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ провСдСния Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΠΈ этих ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ. Π’Π°ΠΊ, административныС Π΄Π°Π½Π½Ρ‹Π΅ ЀРИ содСрТат ΠΈΠ½Ρ„ΠΎΡ€ΠΌΠ°Ρ†ΠΈΡŽ ΠΎΠ±ΠΎ всСх Π»ΠΈΡ†Π°Ρ… со статусом ΠΈΠ½Π²Π°Π»ΠΈΠ΄Π°, ΠΎΠ΄Π½Π°ΠΊΠΎ Π·Π°Π½ΡΡ‚ΠΎΡΡ‚ΡŒ Π² соотвСтствии с этим источником ограничиваСтся прСимущСствСнно Ρ„ΠΎΡ€ΠΌΠ°Π»ΡŒΠ½Ρ‹ΠΌ сСктором экономики. ОбслСдования насСлСния, Π½Π°ΠΏΡ€ΠΎΡ‚ΠΈΠ², ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡŽΡ‚, ΠΏΠΎ мнСнию Π°Π²Ρ‚ΠΎΡ€ΠΎΠ², ΡƒΡ‡Π΅ΡΡ‚ΡŒ всС Ρ„ΠΎΡ€ΠΌΡ‹ занятости, Π½ΠΎ для Π½ΠΈΡ…, ΠΊΠ°ΠΊ источников ΠΈΠ½Ρ„ΠΎΡ€ΠΌΠ°Ρ†ΠΈΠΈ, Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€Π½Π° ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ° Π½Π΅Π΄ΠΎΡƒΡ‡Π΅Ρ‚Π° ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² ΠΈΠ·-Π·Π° Π΄ΠΈΠ·Π°ΠΉΠ½Π° ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΠ΅ΠΌΡ‹Ρ… вопросов, нСТСлания ΠΎΡ‚Π΄Π΅Π»ΡŒΠ½Ρ‹Ρ… Π»ΠΈΡ† рассматриваСмой части насСлСния Π·Π°ΡΠ²Π»ΡΡ‚ΡŒ ΠΎΠ± инвалидности, мСньшСй вСроятности попадания Π½Π΅ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… Π³Ρ€ΡƒΠΏΠΏ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² Π² число рСспондСнтов. ΠšΡ€ΠΎΠΌΠ΅ Ρ‚ΠΎΠ³ΠΎ, Π² статистичСских Π½Π°Π±Π»ΡŽΠ΄Π΅Π½ΠΈΡΡ… Π² Π²ΠΈΠ΄Π΅ административной отчСтности ΠΈ Π² Ρ„ΠΎΡ€ΠΌΠ°Ρ‚Π΅ обслСдований Ρ€Π°Π·Π»ΠΈΡ‡Π°ΡŽΡ‚ΡΡ Π΄Π»ΠΈΠ½Π° обслСдуСмого ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π° ΠΈ мСтодология формирования Π³ΠΎΠ΄ΠΎΠ²Ρ‹Ρ… ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ.АргумСнтируСтся оцСночная позиция Π°Π²Ρ‚ΠΎΡ€ΠΎΠ², Π·Π°ΠΊΠ»ΡŽΡ‡Π°ΡŽΡ‰Π°ΡΡΡ Π² Ρ‚ΠΎΠΌ, Ρ‡Ρ‚ΠΎ Ρ‡ΠΈΡΠ»Π΅Π½Π½ΠΎΡΡ‚ΡŒ занятых ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΎΠ±ΡŠΠ΅ΠΊΡ‚ΠΈΠ²Π½ΠΎ ΠΎΡ‚Ρ€Π°ΠΆΠ°ΡŽΡ‚ административныС Π΄Π°Π½Π½Ρ‹Π΅, Π² Ρ‚ΠΎ врСмя ΠΊΠ°ΠΊ для характСристики полоТСния ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² Π½Π° Ρ€Ρ‹Π½ΠΊΠ΅ Ρ‚Ρ€ΡƒΠ΄Π° цСлСсообразно ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Ρ‚ΡŒ Π΄Π°Π½Π½Ρ‹Π΅ обслСдований насСлСния

    ОбоснованиС ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈΠΊΠΈ расчСта срСднСмСсячной Π·Π°Ρ€Π°Π±ΠΎΡ‚Π½ΠΎΠΉ ΠΏΠ»Π°Ρ‚Ρ‹ Π½Π°Π΅ΠΌΠ½Ρ‹Ρ… Ρ€Π°Π±ΠΎΡ‚Π½ΠΈΠΊΠΎΠ²

    Get PDF
    This article focuses on the explanations of changes in official methodology and new information sources used to calculate the average monthly accrued wages of hired workers (employees) in organizations, individual entrepreneurs and individuals (average monthly income from employment).Based on assessments of representativeness of the Sample Statistical Survey of Income (SSSI) by Russian regions, the authors investigate the possibility of abandoning the conditional Β«spreading coefficientΒ» used in the official method of calculating earnings and switching to the direct use of the results of SSSI of hired workers. The article suggests clarifying the composition of categories of employees in order to make fuller use of statistical reporting data of organizations as the most reliable information source.The changes in the official method of calculation of the employees' earnings, which were discussed in the article, are aimed at increasing the accuracy and reliability of the assessment of this indicator for Russia and Russian regions.Π‘Ρ‚Π°Ρ‚ΡŒΡ посвящСна обоснованию ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ Π°Π»Π³ΠΎΡ€ΠΈΡ‚ΠΌΠΎΠ² ΠΈ ΠΈΠ½Ρ„ΠΎΡ€ΠΌΠ°Ρ†ΠΈΠΎΠ½Π½Ρ‹Ρ… источников, ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΠ΅ΠΌΡ‹Ρ… для расчСта показатСля срСднСмСсячной начислСнной Π·Π°Ρ€Π°Π±ΠΎΡ‚Π½ΠΎΠΉ ΠΏΠ»Π°Ρ‚Ρ‹ Π½Π°Π΅ΠΌΠ½Ρ‹Ρ… Ρ€Π°Π±ΠΎΡ‚Π½ΠΈΠΊΠΎΠ² Π² организациях, Ρƒ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡƒΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΏΡ€Π΅Π΄ΠΏΡ€ΠΈΠ½ΠΈΠΌΠ°Ρ‚Π΅Π»Π΅ΠΉ ΠΈΒ  физичСских Π»ΠΈΡ† (срСднСмСсячного Π΄ΠΎΡ…ΠΎΠ΄Π° ΠΎΡ‚ Ρ‚Ρ€ΡƒΠ΄ΠΎΠ²ΠΎΠΉ Π΄Π΅ΡΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ). На основС ΠΎΡ†Π΅Π½ΠΎΠΊ рСпрСзСнтативности Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΎΠ² Π²Ρ‹Π±ΠΎΡ€ΠΎΡ‡Π½ΠΎΠ³ΠΎ наблюдСния Π΄ΠΎΡ…ΠΎΠ΄ΠΎΠ² насСлСния ΠΏΠΎΒ  ΡΡƒΠ±ΡŠΠ΅ΠΊΡ‚Π°ΠΌ Российской Π€Π΅Π΄Π΅Ρ€Π°Ρ†ΠΈΠΈ Π°Π²Ρ‚ΠΎΡ€Ρ‹ ΠΈΡΡΠ»Π΅Π΄ΡƒΡŽΡ‚ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡ‚ΡŒ ΠΎΡ‚ΠΊΠ°Π·Π° ΠΎΡ‚ условного «коэффициСнта распространСния», примСняСмого Π² ΠΎΡ„ΠΈΡ†ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈΠΊΠ΅ расчСта Π·Π°Ρ€Π°Π±ΠΎΡ‚Π½ΠΎΠΉ ΠΏΠ»Π°Ρ‚Ρ‹, ΠΈ ΠΏΠ΅Ρ€Π΅Ρ…ΠΎΠ΄Π° Π½Π° нСпосрСдствСнноС использованиС Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΎΠ² Π²Ρ‹Π±ΠΎΡ€ΠΎΡ‡Π½ΠΎΠ³ΠΎ наблюдСния Π΄ΠΎΡ…ΠΎΠ΄ΠΎΠ² насСлСния ΠΏΠΎ Π½Π°Π΅ΠΌΠ½Ρ‹ΠΌ Ρ€Π°Π±ΠΎΡ‚Π½ΠΈΠΊΠ°ΠΌ. Π’ ΡΡ‚Π°Ρ‚ΡŒΠ΅ ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½ΠΎ ΡƒΡ‚ΠΎΡ‡Π½Π΅Π½ΠΈΠ΅ состава ΠΊΠ°Ρ‚Π΅Π³ΠΎΡ€ΠΈΠΉ Π½Π°Π΅ΠΌΠ½Ρ‹Ρ… Ρ€Π°Π±ΠΎΡ‚Π½ΠΈΠΊΠΎΠ² с Ρ†Π΅Π»ΡŒΡŽ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ»Π½ΠΎΠ³ΠΎ использования Π΄Π°Π½Π½Ρ‹Ρ… статистичСской отчСтности ΠΎΡ€Π³Π°Π½ΠΈΠ·Π°Ρ†ΠΈΠΉ ΠΊΠ°ΠΊ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π½Π°Π΄Π΅ΠΆΠ½ΠΎΠ³ΠΎ ΠΈΠ½Ρ„ΠΎΡ€ΠΌΠ°Ρ†ΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ источника. АргумСнтированныС Π² ΡΡ‚Π°Ρ‚ΡŒΠ΅ измСнСния ΠΎΡ„ΠΈΡ†ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈΠΊΠΈ расчСта показатСля Π·Π°Ρ€Π°Π±ΠΎΡ‚Π½ΠΎΠΉ ΠΏΠ»Π°Ρ‚Ρ‹ Π½Π°ΠΏΡ€Π°Π²Π»Π΅Π½Ρ‹ Π½Π° ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΠ΅ точности ΠΈ достовСрности ΠΎΡ†Π΅Π½ΠΊΠΈ Π΄Π°Π½Π½ΠΎΠ³ΠΎ показатСля ΠΏΠΎ России ΠΈ ΡΡƒΠ±ΡŠΠ΅ΠΊΡ‚Π°ΠΌ Российской  Π€Π΅Π΄Π΅Ρ€Π°Ρ†ΠΈΠΈ

    Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder

    No full text
    Β© 2020 Future Science Group.Introduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 Β± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: (CYP2C19*1/*1) 2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion: This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.This work was supported by the project titled β€œFundamental research and exploratory research in priority areas of research” of the Russian Science Foundation and by the President’s Grant of state support for the young scientists (project MK-2460.2018.7).info:eu-repo/semantics/publishedVersio

    Rivaroxaban with or without aspirin in stable cardiovascular disease

    No full text
    BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=βˆ’4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events
    corecore